These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19348564)

  • 1. Using plant cells as influenza vaccine substrates.
    Chichester JA; Haaheim LR; Yusibov V
    Expert Rev Vaccines; 2009 Apr; 8(4):493-8. PubMed ID: 19348564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous cell lines as a production system for influenza vaccines.
    Genzel Y; Reichl U
    Expert Rev Vaccines; 2009 Dec; 8(12):1681-92. PubMed ID: 19943763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Influenza vaccine: globalization of public health stakes].
    Collin N; Briand S
    Med Trop (Mars); 2009 Aug; 69(4):322. PubMed ID: 19725377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system.
    Nicolson C; Major D; Wood JM; Robertson JS
    Vaccine; 2005 Apr; 23(22):2943-52. PubMed ID: 15780743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine production capacity for seasonal and pandemic (H1N1) 2009 influenza.
    Collin N; de Radiguès X;
    Vaccine; 2009 Aug; 27(38):5184-6. PubMed ID: 19563891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of cell culture-based influenza vaccine production.
    Perdue ML; Arnold F; Li S; Donabedian A; Cioce V; Warf T; Huebner R
    Expert Rev Vaccines; 2011 Aug; 10(8):1183-94. PubMed ID: 21854311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine manufacturing: challenges and solutions.
    Ulmer JB; Valley U; Rappuoli R
    Nat Biotechnol; 2006 Nov; 24(11):1377-83. PubMed ID: 17093488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FluBlok, a next generation influenza vaccine manufactured in insect cells.
    Cox MM; Hollister JR
    Biologicals; 2009 Jun; 37(3):182-9. PubMed ID: 19297194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza vaccine technologies and the use of the cell-culture process (cell-culture influenza vaccine).
    Mabrouk T; Ellis RW
    Dev Biol (Basel); 2002; 110():125-34. PubMed ID: 12477315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of MDCK cell culture-based influenza vaccines.
    Gregersen JP; Schmitt HJ; Trusheim H; Bröker M
    Future Microbiol; 2011 Feb; 6(2):143-52. PubMed ID: 21366415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and strategies of cell-culture technology for influenza vaccine.
    Feng SZ; Jiao PR; Qi WB; Fan HY; Liao M
    Appl Microbiol Biotechnol; 2011 Feb; 89(4):893-902. PubMed ID: 21063703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technology transfer hub for pandemic influenza vaccine.
    Friede M; Serdobova I; Palkonyay L; Kieny MP
    Vaccine; 2009 Jan; 27(5):631-2. PubMed ID: 19022316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell culture as a substrate for the production of influenza vaccines: memorandum from a WHO meeting.
    Bull World Health Organ; 1995; 73(4):431-5. PubMed ID: 7554013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.
    Hegde NR
    Hum Vaccin Immunother; 2015; 11(5):1223-34. PubMed ID: 25875691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and emerging cell culture manufacturing technologies for influenza vaccines.
    Milián E; Kamen AA
    Biomed Res Int; 2015; 2015():504831. PubMed ID: 25815321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influenza A (H5N1) pandemic prototype vaccine Fluval.
    Vajo Z
    Expert Rev Vaccines; 2009 May; 8(5):619-24. PubMed ID: 19397418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The highly pathogenic avian influenza H5N1 - initial molecular signals for the next influenza pandemic.
    Suzuki Y
    Chang Gung Med J; 2009; 32(3):258-63. PubMed ID: 19527604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plant-made immunogens and effective delivery strategies.
    Paul M; Ma JK
    Expert Rev Vaccines; 2010 Aug; 9(8):821-33. PubMed ID: 20673007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.
    Ichinohe T; Ainai A; Tashiro M; Sata T; Hasegawa H
    Vaccine; 2009 Oct; 27(45):6276-9. PubMed ID: 19840660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.